ATAI — ATAI Life Sciences NV Share Price
0.000.00%
Last trade - 00:00- $340.35m
- $180.33m
- $0.31m
- 38
- 14
- 83
- 41
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.4 | ||
| Price to Tang. Book | 1.4 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1,083.93 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -46.25% | ||
| Return on Equity | -15.97% | ||
| Operating Margin | -40261.78% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 20.38 | 0.23 | 0.31 | 0.3 | 0.3 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. The Company engages in developing various treatments that focuses on various mental health disorders. The Company's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 10th, 2020
- Public Since
- June 18th, 2021
- No. of Shareholders
- 91
- No. of Employees
- 83
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 166,026,396
- Address
- Wallstrasse 16, Berlin, 10179
- Web
- https://atai.life/
- Phone
- +49 8921539035
- Auditors
- Deloitte & Touche LLP
Upcoming Events for ATAI
ATAI Life Sciences NV Annual Shareholders Meeting
ATAI Life Sciences NV Annual Shareholders Meeting
Q2 2024 ATAI Life Sciences NV Earnings Release
Similar to ATAI
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the ATAI Life Sciences NV share price?
As of Today at 19:03 UTC, shares in ATAI Life Sciences NV are trading at $2.05. This share price information is delayed by 15 minutes.
How has the ATAI Life Sciences NV share price performed this year?
Shares in ATAI Life Sciences NV last closed at $2.05 and the price had moved by +5.13% over the past 365 days. In terms of relative price strength the ATAI Life Sciences NV share price has underperformed the S&P500 Index by -15.2% over the past year.
What are the analyst and broker recommendations for ATAI Life Sciences NV?
The overall consensus recommendation for ATAI Life Sciences NV is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the ATAI Life Sciences NV dividend yield?
ATAI Life Sciences NV does not currently pay a dividend.
Does ATAI Life Sciences NV pay a dividend?
ATAI Life Sciences NV does not currently pay a dividend.
When does ATAI Life Sciences NV next pay dividends?
ATAI Life Sciences NV does not currently pay a dividend.
How do I buy ATAI Life Sciences NV shares?
To buy shares in ATAI Life Sciences NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of ATAI Life Sciences NV?
As of the previous close price of $2.05, shares in ATAI Life Sciences NV had a market capitalisation of $340.35m.
Where are ATAI Life Sciences NV shares listed?
Here are the trading details for ATAI Life Sciences NV:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ATAI
What kind of share is ATAI Life Sciences NV?
Based on an overall assessment of its quality, value and momentum ATAI Life Sciences NV is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a ATAI Life Sciences NV share price forecast for 2024?
The analyst consensus target price for shares in ATAI Life Sciences NV is $10.68. That is 420.98% above the last closing price of $2.05.
Analysts covering ATAI Life Sciences NV currently have a consensus Earnings Per Share (EPS) forecast of -$0.78 for the next financial year.
What is the trend in the ATAI Life Sciences NV share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ATAI Life Sciences NV. Over the past six months, its share price has outperformed the S&P500 Index by +32.23%.
As of the last closing price of $2.05, shares in ATAI Life Sciences NV were trading +25.54% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the ATAI Life Sciences NV PE Ratio?
The ATAI Life Sciences NV PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of ATAI Life Sciences NV?
We do not have data on ATAI Life Sciences NV's directors